News & Updates
Part A results from the two-part Phase 2 LILAC study show litifilimab significantly reduced disease activity based on active joint count in people with systemic lupus erythematosus (SLE) compared to placebo Biogen is currently enrolling people with active SLE into two Phase 3 studies in 31 countries worldwide and plans to initiate a pivotal study…
Read More
Not intended for UK-based media First randomized trial in decades to show significant improvement in overall survival in patients with LA SCCHN, reinforcing the transformative potential of xevinapant over standard of care in the curative setting Patients treated with xevinapant plus CRT almost twice as likely to be alive at five years (53% vs 28%)…
Read More
Multicenter basket trial includes cohorts enrolling patients with colorectal and triple negative breast cancer Trial designed to assess efficacy, safety, and evaluate the relationship between tumor Xerna™ TME Panel biomarker subtype and treatment response Excerpt from the Press Release: WALTHAM, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) — OncXerna Therapeutics, Inc. (“OncXerna”), a precision medicine company…
Read More
Study Evaluates the Effectiveness of TherOx Supersaturated Oxygen (SSO2) Therapy in Patients Presenting with Acute Anterior Myocardial Infarction with Successful Reperfusion Compared to Standard Therapy Excerpt from the Press Release: CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the first patient has enrolled…
Read More
– First patient was enrolled as part of a two-stage Phase 2 study evaluating Ashvattha’s subcutaneous (SC) anti-VEGF wet AMD and DME candidate, D-4517.2 – – The first stage of the study will evaluate the safety and relative pharmacodynamic effect of different doses of subcutaneously (SC) administered D-4517.2 compared to intravitreal (IVT) injection of aflibercept,…
Read More
Company Expects Phase 2 Data with Second Drug Candidate (CST-103) in Neurodegenerative Diseases in Third Quarter of 2022 Excerpt from the Press Release: SAN CARLOS, Calif.–(BUSINESS WIRE)–CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced that it has begun dosing patients in a Phase 2a clinical trial with CST-2032,…
Read More
The goal is first-in-human use of NaNots™, injectable absorptive nanoparticles that treat cancer via clearance of tumor-generated immune inhibitors from blood. Excerpt from the Press Release: MILL VALLEY, Calif.–(BUSINESS WIRE)–NaNotics LLC, a biopharmaceutical company developing NaNots™, novel subtractive nanoparticles that treat disease by capturing and clearing pathogenic molecules from blood, today announced a research collaboration…
Read More
— Company Expects to Announce Topline Data from Study in Adults 65 Years and Older in the First Half of 2023 — — Vaxcyte Remains on Track to Announce Topline Data from the Phase 1 and Phase 2 Portions of the VAX-24 Proof-of-Concept Study in Adults Aged 18-64 in October or November 2022 — —…
Read More
Expected to Accelerate Sales Opportunities in Doctor’s Office and Wound Clinics Excerpt from the Press Release: FRAMINGHAM, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) — Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that it has launched a multi-site clinical study…
Read More
Data published in bioRxiv shows ELI-005 administration safely promotes robust cellular and humoral immunity through potent and targeted engagement of the lymph nodes in mice and non-human primates (NHPs) Prime-boost administration of ELI-005 induced potent Spike receptor binding domain (RBD)-specific effector cytokine-producing T cell responses in mouse and NHP peripheral blood showing cross-reactivity against variants…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?